REFERENCES

1. American Cancer Society. Cancer Facts and Figures 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed August 24, 2012.


Continue Reading

2. Patil N, Abba M, Allgayer H. Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics. 2012;6:221-231.   

3. Zhu J, Sharma DB, Gray SW, et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA. 2012;307(15):1593-1601.

4. Laskin J, Crinò L, Felip E, et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol. 2012;7(1):203-211.

5. Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma. J Clin Onc. 2012;30(20):2509-2515.

6. U.S. National Institutes of Health. Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy. http://clinicaltrials.gov/ct2/show/NCT00365547?term=Bevacizumab+lung+cancer&rank=4. Accessed August 24, 2012.

7. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.  Lancet. 2009;373(9674):1525-1531.

8. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13(1):33-42.

9. Kim ES, Neubauer MA, Cohn AL, et al. SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy. Paper presented at the 2012 Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, June 2012. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92436. Accessed August 24, 2012.

10. U.S. National Institutes of Health. High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. http://clinicaltrials.gov/ct2/show/NCT00533949?term=cetuximab+lung+cancer&rank=11. Accessed August 24, 2012.

11. Grossi F. Management of non-small cell lung in cancer patients with stable disease. Drugs. 2012; 72 Suppl 1:20-27. doi: 10.2165/1163013-S0-000000000-00000.